TENXTENAX THERAPEUTICS, INC.同业对比
TENAX THERAPEUTICS, INC. 与Pharmaceutical Preparations的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Pharmaceutical Preparations)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TENX本股 | $68M#8 | — | 0.6x#3 | — | — | -198.9%#15 | — | -46.3%#6 | — | — | -74.6%#15 | — |
| PDSB | $73M#1 | — | — | — | — | 8.3%#8 | — | — | -541.6%#3 | — | 46.1%#2 | — |
| MNOV | $72M#2 | — | 1.9x#8 | 176.6x#6 | — | 8.6%#7 | -3242.5%#7 | 32.2%#1 | — | — | 1.7%#5 | — |
| COYA | $71M#3 | — | 1.6x#7 | 9.0x#5 | 123.6%#2 | -42.6%#13 | -283.9%#6 | -49.0%#7 | — | — | -48.2%#11 | — |
| PMVP | $71M#4 | — | 1.0x#5 | — | — | -32.0%#11 | — | -108.7%#11 | — | — | 0.4%#6 | — |
| SDEV | $71M#5 | — | 0.4x#1 | 7.2x#4 | -6.4%#6 | -8632.9%#16 | -86.3%#4 | -346.3%#13 | -4.8%#1 | — | -81.6%#16 | 6.8%#1 |
| CRBP | $69M#6 | — | 0.7x#4 | — | -100.0%#8 | -95.3%#14 | — | -76.8%#8 | -93.1%#2 | — | -68.1%#14 | — |
| MAIA | $68M#7 | — | 3.3x#10 | — | — | 3.7%#9 | — | -108.3%#10 | — | — | 3.2%#4 | — |
| CPIX | $67M#9 | — | 3.8x#11 | 1.5x#1 | 17.6%#3 | 56.2%#4 | -6.3%#3 | -16.3%#4 | — | — | 64.0%#1 | — |
| CING | $66M#10 | — | 2.8x#9 | — | — | -35.6%#12 | — | -95.7%#9 | — | — | 23.6%#3 | — |
| FBIO | — | 0.7x#1 | — | — | 9.7%#4 | 76.2%#3 | -111.0%#5 | 22.5%#2 | — | — | -20.1%#9 | — |
| EVFM | $63M#11 | — | — | 3.1x#2 | 4.2%#5 | 104.4%#2 | 16.7%#2 | — | — | — | 0.3%#7 | — |
| SPRO | $62M#12 | 7.6x#2 | 1.4x#6 | 4.9x#3 | 3292.5%#1 | 112.5%#1 | 50.2%#1 | 19.4%#3 | — | — | -54.9%#12 | — |
| CLNN | $61M#13 | — | — | 303.8x#7 | -41.5%#7 | 33.6%#6 | -11541.5%#8 | — | — | — | -61.6%#13 | — |
| TELO | $59M#14 | — | 11.8x#12 | — | — | 37.0%#5 | — | -206.9%#12 | — | — | -39.2%#10 | — |
| XBIT | $59M#15 | — | 0.5x#2 | — | -100.0%#8 | -18.2%#10 | — | -35.5%#5 | — | — | -9.5%#8 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-11-04。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议